Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.

@article{Miller2011EffectivenessOT,
  title={Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.},
  author={Elizabeth L. Miller and Nicholas John Abbott Andrews and Pauline A. Waight and Mary P. E. Slack and Robert C. George},
  journal={Vaccine},
  year={2011},
  volume={29 49},
  pages={
          9127-31
        }
}
Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 82 CITATIONS, ESTIMATED 53% COVERAGE

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Infants, Children, and Adolescents

  • Paediatric drugs
  • 2013
VIEW 8 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
VIEW 2 EXCERPTS
CITES RESULTS

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

( PCV 13 ) elicits cross - functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6 C and 7 A

SA Madhi, P Adrian, +3 authors T Little
  • vaccine
  • 2011

Quarterly vaccination coverage statistics for children aged up to five years in the UK ( COVER programme ) : January to March 2011

H Rinta-Kokko, R Dagan, N Givon-Lavi, K Auranen
  • Health Prot Rep
  • 2011

Response to : Hausdorff WP , Hoet B , Schuerman L : Do pneumococcal conjugate vaccines provide any cross - protection against serotype 19 A ?

P Paradiso
  • Pediatr Infect Dis J
  • 2010